|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HAS2 |
Gene summary for HAS2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HAS2 | Gene ID | 3037 |
| Gene name | hyaluronan synthase 2 | |
| Gene Alias | HAS2 | |
| Cytomap | 8q24.13 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q92819 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3037 | HAS2 | PTC04 | Human | Thyroid | PTC | 5.67e-05 | 1.87e-01 | 0.1927 |
| 3037 | HAS2 | ATC09 | Human | Thyroid | ATC | 5.47e-05 | 2.59e-01 | 0.2871 |
| 3037 | HAS2 | ATC12 | Human | Thyroid | ATC | 7.68e-49 | 1.32e+00 | 0.34 |
| 3037 | HAS2 | ATC13 | Human | Thyroid | ATC | 1.21e-24 | 5.23e-01 | 0.34 |
| 3037 | HAS2 | ATC1 | Human | Thyroid | ATC | 8.73e-06 | 3.31e-01 | 0.2878 |
| 3037 | HAS2 | ATC2 | Human | Thyroid | ATC | 7.49e-03 | 2.46e-01 | 0.34 |
| 3037 | HAS2 | ATC4 | Human | Thyroid | ATC | 7.01e-58 | 1.55e+00 | 0.34 |
| 3037 | HAS2 | ATC5 | Human | Thyroid | ATC | 2.11e-25 | 5.61e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022604112 | Thyroid | PTC | regulation of cell morphogenesis | 165/5968 | 309/18723 | 2.60e-15 | 1.82e-13 | 165 |
| GO:0010810112 | Thyroid | PTC | regulation of cell-substrate adhesion | 113/5968 | 221/18723 | 1.87e-09 | 5.28e-08 | 113 |
| GO:0031589111 | Thyroid | PTC | cell-substrate adhesion | 169/5968 | 363/18723 | 2.73e-09 | 7.57e-08 | 169 |
| GO:0010769111 | Thyroid | PTC | regulation of cell morphogenesis involved in differentiation | 57/5968 | 96/18723 | 2.50e-08 | 5.62e-07 | 57 |
| GO:001072018 | Thyroid | PTC | positive regulation of cell development | 138/5968 | 298/18723 | 1.13e-07 | 2.22e-06 | 138 |
| GO:0010770111 | Thyroid | PTC | positive regulation of cell morphogenesis involved in differentiation | 48/5968 | 79/18723 | 1.15e-07 | 2.26e-06 | 48 |
| GO:000182215 | Thyroid | PTC | kidney development | 133/5968 | 293/18723 | 7.57e-07 | 1.18e-05 | 133 |
| GO:0010811112 | Thyroid | PTC | positive regulation of cell-substrate adhesion | 65/5968 | 123/18723 | 1.10e-06 | 1.62e-05 | 65 |
| GO:000165517 | Thyroid | PTC | urogenital system development | 149/5968 | 338/18723 | 1.41e-06 | 2.01e-05 | 149 |
| GO:007200114 | Thyroid | PTC | renal system development | 135/5968 | 302/18723 | 1.76e-06 | 2.43e-05 | 135 |
| GO:0034446111 | Thyroid | PTC | substrate adhesion-dependent cell spreading | 58/5968 | 108/18723 | 2.07e-06 | 2.82e-05 | 58 |
| GO:0001667112 | Thyroid | PTC | ameboidal-type cell migration | 198/5968 | 475/18723 | 3.36e-06 | 4.34e-05 | 198 |
| GO:0010634111 | Thyroid | PTC | positive regulation of epithelial cell migration | 85/5968 | 176/18723 | 3.83e-06 | 4.80e-05 | 85 |
| GO:1900024111 | Thyroid | PTC | regulation of substrate adhesion-dependent cell spreading | 35/5968 | 57/18723 | 4.20e-06 | 5.20e-05 | 35 |
| GO:0048511111 | Thyroid | PTC | rhythmic process | 131/5968 | 298/18723 | 7.06e-06 | 8.33e-05 | 131 |
| GO:000183715 | Thyroid | PTC | epithelial to mesenchymal transition | 76/5968 | 157/18723 | 1.10e-05 | 1.21e-04 | 76 |
| GO:1900026110 | Thyroid | PTC | positive regulation of substrate adhesion-dependent cell spreading | 26/5968 | 41/18723 | 3.23e-05 | 3.07e-04 | 26 |
| GO:0010631111 | Thyroid | PTC | epithelial cell migration | 149/5968 | 357/18723 | 4.83e-05 | 4.33e-04 | 149 |
| GO:0090132111 | Thyroid | PTC | epithelium migration | 149/5968 | 360/18723 | 7.89e-05 | 6.74e-04 | 149 |
| GO:0034612111 | Thyroid | PTC | response to tumor necrosis factor | 109/5968 | 253/18723 | 1.08e-04 | 8.69e-04 | 109 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HAS2 | SNV | Missense_Mutation | novel | c.1015N>A | p.Glu339Lys | p.E339K | Q92819 | protein_coding | deleterious(0.01) | possibly_damaging(0.897) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| HAS2 | SNV | Missense_Mutation | novel | c.1219N>A | p.Leu407Ile | p.L407I | Q92819 | protein_coding | tolerated(0.13) | benign(0.377) | TCGA-A2-A3XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD |
| HAS2 | SNV | Missense_Mutation | c.799N>C | p.Glu267Gln | p.E267Q | Q92819 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| HAS2 | SNV | Missense_Mutation | c.316N>T | p.Val106Leu | p.V106L | Q92819 | protein_coding | tolerated(0.22) | benign(0.036) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| HAS2 | deletion | Frame_Shift_Del | c.464delN | p.Lys155ArgfsTer17 | p.K155Rfs*17 | Q92819 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| HAS2 | SNV | Missense_Mutation | c.616N>A | p.Asp206Asn | p.D206N | Q92819 | protein_coding | deleterious(0) | benign(0.211) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
| HAS2 | SNV | Missense_Mutation | c.1079N>A | p.Arg360Gln | p.R360Q | Q92819 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HAS2 | SNV | Missense_Mutation | c.1585N>A | p.Leu529Met | p.L529M | Q92819 | protein_coding | tolerated(0.06) | benign(0.141) | TCGA-AA-3875-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HAS2 | SNV | Missense_Mutation | c.1289A>C | p.Asn430Thr | p.N430T | Q92819 | protein_coding | tolerated(0.21) | possibly_damaging(0.506) | TCGA-F4-6854-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HAS2 | SNV | Missense_Mutation | rs202113498 | c.206G>A | p.Arg69Gln | p.R69Q | Q92819 | protein_coding | deleterious(0.03) | benign(0.013) | TCGA-DY-A1DF-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |